Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-09-28

AUTHORS

Yoshihiro Tanaka, Kazuhiro Yoshida, Yuichi Sanada, Shinji Osada, Kazuya Yamaguchi, Takao Takahashi

ABSTRACT

Background and purposeThe optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinoma.Patients and methodWe studied a total of 18 patients who had previously untreated thoracic esophageal squamous cell carcinoma with T4 tumors and/or metastasis. The patients received an infusion of docetaxel at different dose levels (levels 1, 2, 3: 30, 35, 40 mg/m2, respectively) and an infusion of cisplatin (40 mg/m2) on days 1 and 15 plus a continuous infusion of 5-FU (400 mg/m2/day) on days 1–5 and 15–19.ResultsDose-limiting toxicities (DLT) included febrile neutropenia and leukopenia. DLT occurred in 2 of 6 patients at level 1, 2 and in 3 of 6 patients at level 3. The response rate was 88.9%, including a complete response rate of 33.3%.ConclusionsTo minimize toxicity and maximize dose intensity, we elected to investigate a biweekly regimen. The maximum tolerated dose was level 3, and the recommended dose was determined to be docetaxel 35 mg/m2 with cisplatin 40 mg/m2 plus 5-FU 400 mg/m2, administered biweekly. This regimen was tolerable and highly active. A phase II study has been started. More... »

PAGES

1159-1165

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-010-1447-1

DOI

http://dx.doi.org/10.1007/s00280-010-1447-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1022617962

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20878160


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Squamous Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cisplatin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Docetaxel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Esophageal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Taxoids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanaka", 
        "givenName": "Yoshihiro", 
        "id": "sg:person.01355404535.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355404535.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yoshida", 
        "givenName": "Kazuhiro", 
        "id": "sg:person.015065301357.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015065301357.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sanada", 
        "givenName": "Yuichi", 
        "id": "sg:person.01105006711.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105006711.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Osada", 
        "givenName": "Shinji", 
        "id": "sg:person.0637354716.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637354716.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamaguchi", 
        "givenName": "Kazuya", 
        "id": "sg:person.012207431752.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012207431752.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Takao", 
        "id": "sg:person.010673416164.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673416164.98"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6603585", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052458544", 
          "https://doi.org/10.1038/sj.bjc.6603585"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/277665a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005302260", 
          "https://doi.org/10.1038/277665a0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-09-28", 
    "datePublishedReg": "2010-09-28", 
    "description": "Background and purposeThe optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinoma.Patients and methodWe studied a total of 18 patients who had previously untreated thoracic esophageal squamous cell carcinoma with T4 tumors and/or metastasis. The patients received an infusion of docetaxel at different dose levels (levels 1, 2, 3: 30, 35, 40\u00a0mg/m2, respectively) and an infusion of cisplatin (40\u00a0mg/m2) on days 1 and 15 plus a continuous infusion of 5-FU (400\u00a0mg/m2/day) on days 1\u20135 and 15\u201319.ResultsDose-limiting toxicities (DLT) included febrile neutropenia and leukopenia. DLT occurred in 2 of 6 patients at level 1, 2 and in 3 of 6 patients at level 3. The response rate was 88.9%, including a complete response rate of 33.3%.ConclusionsTo minimize toxicity and maximize dose intensity, we elected to investigate a biweekly regimen. The maximum tolerated dose was level 3, and the recommended dose was determined to be docetaxel 35\u00a0mg/m2 with cisplatin 40\u00a0mg/m2 plus 5-FU 400\u00a0mg/m2, administered biweekly. This regimen was tolerable and highly active. A phase II study has been started.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-010-1447-1", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "66"
      }
    ], 
    "keywords": [
      "esophageal squamous cell carcinoma", 
      "squamous cell carcinoma", 
      "advanced esophageal squamous cell carcinoma", 
      "dose-escalation study", 
      "cell carcinoma", 
      "day 1", 
      "thoracic esophageal squamous cell carcinoma", 
      "response rate", 
      "phase I dose-escalation study", 
      "I dose-escalation study", 
      "optimal chemotherapeutic protocols", 
      "infusion of docetaxel", 
      "complete response rate", 
      "phase II study", 
      "infusion of cisplatin", 
      "different dose levels", 
      "docetaxel 35", 
      "cisplatin 40", 
      "biweekly docetaxel", 
      "febrile neutropenia", 
      "T4 tumors", 
      "dose intensity", 
      "II study", 
      "biweekly regimen", 
      "esophageal cancer", 
      "continuous infusion", 
      "chemotherapeutic protocols", 
      "optimal dose", 
      "patients", 
      "dose levels", 
      "carcinoma", 
      "docetaxel", 
      "infusion", 
      "level 3", 
      "cisplatin", 
      "dose", 
      "regimen", 
      "toxicity", 
      "level 1", 
      "neutropenia", 
      "leukopenia", 
      "chemotherapy", 
      "metastasis", 
      "tumors", 
      "cancer", 
      "study", 
      "treatment", 
      "total", 
      "MethodWe", 
      "m2", 
      "rate", 
      "ConclusionsTo", 
      "DLT", 
      "levels", 
      "protocol", 
      "background", 
      "intensity", 
      "maximum"
    ], 
    "name": "Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study", 
    "pagination": "1159-1165", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1022617962"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-010-1447-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20878160"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-010-1447-1", 
      "https://app.dimensions.ai/details/publication/pub.1022617962"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_502.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-010-1447-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1447-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1447-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1447-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-010-1447-1'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      21 PREDICATES      102 URIs      92 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-010-1447-1 schema:about N1c6aaf4c6fdb4a87a2e084235180cf10
2 N1cb01e9dc97e49eab8ebaa84cda54d04
3 N2493f48577534bcca038145f028b30b3
4 N2cd73299047b4bcd8f8763fe0d10b873
5 N3468085a93974f028484c7c967e37c78
6 N34946a54655f4e7cac0e17b30ca7dc66
7 N4220e346295e4c3fab4f7bf70cb9600a
8 N65937f30b6fe4c9c9344df78ea6d540a
9 N8291acf05a2e43258f6eb5dc4e320b98
10 Ncdc19b1fde454006848a96db9f6a0093
11 Ncdd9120f1a254450acb6fbbe8776a821
12 Nd14d2c0fd3494088b505937c916db5b6
13 Nee7ad1fae0d14bc08366aba453cdb924
14 Nf342a354676941778db54fd9754234a6
15 Nf64a6ea75bb547cebc6cd604b71a1b7c
16 Nfb3f6e43bb50419b885cc4348277a21d
17 Nfe1358fd74b7417299b81cba1ec94cb8
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Nd3750967d7214122bdaa75019cb0ee36
21 schema:citation sg:pub.10.1038/277665a0
22 sg:pub.10.1038/sj.bjc.6603585
23 schema:datePublished 2010-09-28
24 schema:datePublishedReg 2010-09-28
25 schema:description Background and purposeThe optimal chemotherapeutic protocol for the treatment of esophageal cancer has not yet been established. A dose-escalation study of docetaxel combined with cisplatin and 5-fluorouracil (5-FU) was performed to determine the optimal dose in patients with advanced esophageal squamous cell carcinoma.Patients and methodWe studied a total of 18 patients who had previously untreated thoracic esophageal squamous cell carcinoma with T4 tumors and/or metastasis. The patients received an infusion of docetaxel at different dose levels (levels 1, 2, 3: 30, 35, 40 mg/m2, respectively) and an infusion of cisplatin (40 mg/m2) on days 1 and 15 plus a continuous infusion of 5-FU (400 mg/m2/day) on days 1–5 and 15–19.ResultsDose-limiting toxicities (DLT) included febrile neutropenia and leukopenia. DLT occurred in 2 of 6 patients at level 1, 2 and in 3 of 6 patients at level 3. The response rate was 88.9%, including a complete response rate of 33.3%.ConclusionsTo minimize toxicity and maximize dose intensity, we elected to investigate a biweekly regimen. The maximum tolerated dose was level 3, and the recommended dose was determined to be docetaxel 35 mg/m2 with cisplatin 40 mg/m2 plus 5-FU 400 mg/m2, administered biweekly. This regimen was tolerable and highly active. A phase II study has been started.
26 schema:genre article
27 schema:isAccessibleForFree true
28 schema:isPartOf N32c35fc9d7674cb9b80eca0c2845fa8c
29 N924f110645b74c3caf927d1fd16ddafd
30 sg:journal.1088364
31 schema:keywords ConclusionsTo
32 DLT
33 I dose-escalation study
34 II study
35 MethodWe
36 T4 tumors
37 advanced esophageal squamous cell carcinoma
38 background
39 biweekly docetaxel
40 biweekly regimen
41 cancer
42 carcinoma
43 cell carcinoma
44 chemotherapeutic protocols
45 chemotherapy
46 cisplatin
47 cisplatin 40
48 complete response rate
49 continuous infusion
50 day 1
51 different dose levels
52 docetaxel
53 docetaxel 35
54 dose
55 dose intensity
56 dose levels
57 dose-escalation study
58 esophageal cancer
59 esophageal squamous cell carcinoma
60 febrile neutropenia
61 infusion
62 infusion of cisplatin
63 infusion of docetaxel
64 intensity
65 leukopenia
66 level 1
67 level 3
68 levels
69 m2
70 maximum
71 metastasis
72 neutropenia
73 optimal chemotherapeutic protocols
74 optimal dose
75 patients
76 phase I dose-escalation study
77 phase II study
78 protocol
79 rate
80 regimen
81 response rate
82 squamous cell carcinoma
83 study
84 thoracic esophageal squamous cell carcinoma
85 total
86 toxicity
87 treatment
88 tumors
89 schema:name Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study
90 schema:pagination 1159-1165
91 schema:productId N79a46e5f1eca460188afceb62733a197
92 Nb2b73557dbf44203a8f11e24d9476cd5
93 Ne55dbcf4ca284e339fa8f19e1b2ec22b
94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022617962
95 https://doi.org/10.1007/s00280-010-1447-1
96 schema:sdDatePublished 2022-11-24T20:54
97 schema:sdLicense https://scigraph.springernature.com/explorer/license/
98 schema:sdPublisher Nd470a2a893494525a0bc60be2002ea14
99 schema:url https://doi.org/10.1007/s00280-010-1447-1
100 sgo:license sg:explorer/license/
101 sgo:sdDataset articles
102 rdf:type schema:ScholarlyArticle
103 N1c6aaf4c6fdb4a87a2e084235180cf10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Cisplatin
105 rdf:type schema:DefinedTerm
106 N1cb01e9dc97e49eab8ebaa84cda54d04 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Taxoids
108 rdf:type schema:DefinedTerm
109 N2493f48577534bcca038145f028b30b3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Dose-Response Relationship, Drug
111 rdf:type schema:DefinedTerm
112 N2cd73299047b4bcd8f8763fe0d10b873 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Humans
114 rdf:type schema:DefinedTerm
115 N32c35fc9d7674cb9b80eca0c2845fa8c schema:issueNumber 6
116 rdf:type schema:PublicationIssue
117 N3468085a93974f028484c7c967e37c78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Adult
119 rdf:type schema:DefinedTerm
120 N34946a54655f4e7cac0e17b30ca7dc66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Maximum Tolerated Dose
122 rdf:type schema:DefinedTerm
123 N4220e346295e4c3fab4f7bf70cb9600a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Middle Aged
125 rdf:type schema:DefinedTerm
126 N65937f30b6fe4c9c9344df78ea6d540a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Treatment Outcome
128 rdf:type schema:DefinedTerm
129 N71db746a8f5d4db4a8e53a9deb7ea818 rdf:first sg:person.015065301357.03
130 rdf:rest Ne89c36f3666e4ec68215f6c2734f8130
131 N79a46e5f1eca460188afceb62733a197 schema:name doi
132 schema:value 10.1007/s00280-010-1447-1
133 rdf:type schema:PropertyValue
134 N8291acf05a2e43258f6eb5dc4e320b98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Drug Administration Schedule
136 rdf:type schema:DefinedTerm
137 N924f110645b74c3caf927d1fd16ddafd schema:volumeNumber 66
138 rdf:type schema:PublicationVolume
139 N93e60ceee708485bbebd2fe42ed989a5 rdf:first sg:person.010673416164.98
140 rdf:rest rdf:nil
141 N9ebcf3c6008e41b3824509f00c1117ef rdf:first sg:person.0637354716.81
142 rdf:rest Nd2716d2ce9204f3e8002e959d7c09a73
143 Nb2b73557dbf44203a8f11e24d9476cd5 schema:name dimensions_id
144 schema:value pub.1022617962
145 rdf:type schema:PropertyValue
146 Ncdc19b1fde454006848a96db9f6a0093 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Carcinoma, Squamous Cell
148 rdf:type schema:DefinedTerm
149 Ncdd9120f1a254450acb6fbbe8776a821 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Fluorouracil
151 rdf:type schema:DefinedTerm
152 Nd14d2c0fd3494088b505937c916db5b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Docetaxel
154 rdf:type schema:DefinedTerm
155 Nd2716d2ce9204f3e8002e959d7c09a73 rdf:first sg:person.012207431752.15
156 rdf:rest N93e60ceee708485bbebd2fe42ed989a5
157 Nd3750967d7214122bdaa75019cb0ee36 rdf:first sg:person.01355404535.58
158 rdf:rest N71db746a8f5d4db4a8e53a9deb7ea818
159 Nd470a2a893494525a0bc60be2002ea14 schema:name Springer Nature - SN SciGraph project
160 rdf:type schema:Organization
161 Ne55dbcf4ca284e339fa8f19e1b2ec22b schema:name pubmed_id
162 schema:value 20878160
163 rdf:type schema:PropertyValue
164 Ne89c36f3666e4ec68215f6c2734f8130 rdf:first sg:person.01105006711.43
165 rdf:rest N9ebcf3c6008e41b3824509f00c1117ef
166 Nee7ad1fae0d14bc08366aba453cdb924 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Female
168 rdf:type schema:DefinedTerm
169 Nf342a354676941778db54fd9754234a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Antineoplastic Combined Chemotherapy Protocols
171 rdf:type schema:DefinedTerm
172 Nf64a6ea75bb547cebc6cd604b71a1b7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Esophageal Neoplasms
174 rdf:type schema:DefinedTerm
175 Nfb3f6e43bb50419b885cc4348277a21d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Aged
177 rdf:type schema:DefinedTerm
178 Nfe1358fd74b7417299b81cba1ec94cb8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Male
180 rdf:type schema:DefinedTerm
181 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
182 schema:name Medical and Health Sciences
183 rdf:type schema:DefinedTerm
184 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
185 schema:name Oncology and Carcinogenesis
186 rdf:type schema:DefinedTerm
187 sg:journal.1088364 schema:issn 0344-5704
188 1432-0843
189 schema:name Cancer Chemotherapy and Pharmacology
190 schema:publisher Springer Nature
191 rdf:type schema:Periodical
192 sg:person.010673416164.98 schema:affiliation grid-institutes:None
193 schema:familyName Takahashi
194 schema:givenName Takao
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010673416164.98
196 rdf:type schema:Person
197 sg:person.01105006711.43 schema:affiliation grid-institutes:None
198 schema:familyName Sanada
199 schema:givenName Yuichi
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105006711.43
201 rdf:type schema:Person
202 sg:person.012207431752.15 schema:affiliation grid-institutes:None
203 schema:familyName Yamaguchi
204 schema:givenName Kazuya
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012207431752.15
206 rdf:type schema:Person
207 sg:person.01355404535.58 schema:affiliation grid-institutes:None
208 schema:familyName Tanaka
209 schema:givenName Yoshihiro
210 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355404535.58
211 rdf:type schema:Person
212 sg:person.015065301357.03 schema:affiliation grid-institutes:None
213 schema:familyName Yoshida
214 schema:givenName Kazuhiro
215 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015065301357.03
216 rdf:type schema:Person
217 sg:person.0637354716.81 schema:affiliation grid-institutes:None
218 schema:familyName Osada
219 schema:givenName Shinji
220 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0637354716.81
221 rdf:type schema:Person
222 sg:pub.10.1038/277665a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005302260
223 https://doi.org/10.1038/277665a0
224 rdf:type schema:CreativeWork
225 sg:pub.10.1038/sj.bjc.6603585 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052458544
226 https://doi.org/10.1038/sj.bjc.6603585
227 rdf:type schema:CreativeWork
228 grid-institutes:None schema:alternateName Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan
229 schema:name Department of Surgical Oncology, Gifu Graduate School of Medicine, 1-1, Yanagido, 501-1194, Gifu city, Gifu, Japan
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...